newsfilter
← Latest News
GlobeNewswire·

Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates

Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of repotrectinib Initiated the Phase 1b/2 SHIELD-2 combination study of elzovantinib and aumolertinib i